News & Updates
Showing Multidisciplinary articles
Showing
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.
Triptans work best against migraine episodes
For adults with migraine, the drugs with the best profile include eletriptan, rizatriptan, sumatriptan, and zolmitriptan, suggests a study. These agents are more effective than most available medications on the market such as lasmiditan, rimegepant, and ubrogepant.
AI tool reads histology slides to predict lung cancer mutations
DeepGEM, a novel tool that harnesses artificial intelligence (AI), delivers accurate, timely, and economical gene mutation prediction from routinely acquired histology slides, enhancing the efficiency of lung cancer mutation screening, according to a study.
Real-world study supports tralokinumab for difficult-to-treat AD
Interim data from the real-world TRACE study confirm the benefits of the high-affinity monoclonal antibody tralokinumab for individuals with moderate-to-severe head and neck atopic dermatitis (H&N AD) after up to 9 months of treatment.
